Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PPA1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PPA1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active enzyme format for high-throughput screening. |
View PPA1 Products |
| Gene Delivery | PPA1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View PPA1 Products |
| Benchmark Ab | Anti-PPA1 Recombinant Antibody High-affinity positive control for Western Blot, IHC, and ELISA validation. |
View PPA1 Products |
| Validator | PPA1 siRNA Set Target-specific knockdown verification to confirm phenotype and target engagement. |
View PPA1 Products |
| Related Target A | PPA2 (Inorganic Pyrophosphatase 2) Mitochondrial homolog. Critical counter-screening target to ensure drug safety and avoid cardiotoxicity. |
View PPA2 Products |
| Related Target B | ENPP1 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 1) Upstream regulator of pyrophosphate (PPi) generation; synergistic target in purinergic signaling and calcification pathways. |
View ENPP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Off-target toxicity screening (PPA1 vs PPA2) | High-purity human PPA1 and PPA2 proteins available with verified sequence identity and enzymatic activity profiles. |
| High background phosphate contamination in HTS | Ultra-low phosphate background in recombinant protein preparations, minimizing false positives in Malachite Green assays. |
| Lack of validated positive controls | Sequence-derived benchmark recombinant antibodies for highly specific target detection. |
| Target validation in phenotypic models | Pre-designed, sequence-verified siRNA pools for robust knock-down validation. |
Live PPA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PPA1 therapeutics is intensifying, with major players shifting focus from traditional non-specific metabolic inhibitors to highly selective small-molecule inhibitors and RNA-targeting therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting PPA1-driven chemoresistance and its role in the epithelial-mesenchymal transition (EMT) of solid tumors.
PPA1 (Inorganic Pyrophosphatase 1) serves as a critical metabolic engine by hydrolyzing inorganic pyrophosphate (PPi) to inorganic phosphate (Pi), driving biosynthetic reactions forward. Its overexpression in breast, gastric, and colorectal cancers correlates with poor prognosis, making it a highly sought-after intracellular target for small-molecule drug discovery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Biotech Startups, Academic Consortia | Colorectal Cancer, Gastric Cancer | Enzymatic Assay & Selectivity Screening (Need highly active WT PPA1 and PPA2) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Solid Tumors, Chemoresistant Cancers | In Vitro Knockdown & Functional Rescue (Need Lentivirus and validated siRNA) |
| Monoclonal Antibodies (for Diagnostics) | Diagnostic Developers | Companion Diagnostics (CDx) | High-affinity detection (Need recombinant antigen for immunization and screening) |